Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs

Variant Bio, which debuted Thursday with $16 million in Series A financing, is betting that its narrower strategy of identifying small groups of “outlier humans” with variations in DNA that affect disease risk will prove both quicker and cheaper.